Acceleron promised they had great data on sotatercept in late January. But was it good enough to justify a doubling of the stock price?
The stock price of Acceleron $XLRN has almost doubled since the biotech announced in late January that its mid-stage study of sotatercept cleared the important endpoints for pulmonary arterial hypertension, or PAH — even though the biotech told investors to wait for the data.
The hard results landed Wednesday afternoon, and now analysts who outlined a potential blockbuster return can start sorting out whether the giddy market response — adding more than $2 billion to the market cap — was warranted.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.